Glioblastoma (GBM) remains lethal despite multimodal therapy, with median survival under 15 months. Immunotherapy has failed in over 100 clinical trials due to three fundamental barriers: inadequate immune priming in "cold" tumors, blood–brain barrier (BBB) exclusion of therapeutics, and profound local immunosuppression.
-
Updated
Dec 23, 2025 - TeX